© 2012 Future Path Medical Holding Company, LLC All Rights Reserved
The Future Path Medical (FPM) product families - iBag™ and UroSense™ consist of innovative patented technologies. Innovations in these families include; industrial designed disposables engineered to specific uses in either the home market or the intensive care unit. FPM has detailed the processes dealing with urine handling in these markets and created patent pending low-cost sensors, a Wi-Mitter™ wireless system that converts urine fill and temperature data into time-stamped “IP” (or internet protocol). The previously unavailable or expensive data is now offered at a fraction of the cost of any current smart “clinical fluid” systems and allows patient and fluid information to be available anywhere.
The technology is currently going through the FDA 510 K compliance process. Future Path Medical (FPM) is still accepting new investors and strategic partners with the right hearts and minds. We are currently a pre-revenue company with a disruptive patented offering in a mature market.
Investment Inquiries - info@future-path.net
Notes: Clinical fluid management technology includes solutions for incontinence, bladder and urine monitoring, and hydration management through intravenous delivery. These solution areas will experience significant increases to both patient safety and nursing productivity.
FPM is launching two new families of Urological Monitoring products based on expert industrial design, wireless transmission, and low-cost sensor technologies. The iBag™ product family will be targeted at home care (e.g. the spinal cord injured, quadriplegic disabled market) and UroSense™ will be targeted for the needs of the “intensivist” and the hospital intensive care unit (ICU) nursing and staff.
Future Path Medical will deliver reduced labor and early infection detection (e.g. UTIs) for the ICU patients who receive catheters, a staggering 70% of whom get UTIs within their first 72 hours of catheterization. Further, catheter associated urinary tract infections are the leading cause of nosocomial infections, which as of October 2008 are no longer being reimbursed by CMS per their announcement.
